Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Compare the antitumor activity in first-line therapy of paclitaxel- and carboplatin-combination therapy plus enzastaurin followed by enzastaurin maintenance therapy (Regimen A), versus paclitaxel- and carboplatin-combination therapy plus placebo followed by placebo as a maintenance (Regimen B), as measured by progression-free survival (PFS).
Critère d'inclusion
- Patients with a histologic diagnosis of FIGO Stage IIB, IIC, III, or IV advanced invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma